View ValuationReboost Blockchain 将来の成長Future 基準チェック /06現在、 Reboost Blockchainの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • 2hNo independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Jean-Charles Dudek was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 07Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026. Location: 3 rue d heliopolis, paris Franceお知らせ • Feb 17Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction.Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction on February 15, 2026. The transaction is subject to both shareholder approval and regulatory clearance before it can be finalized. The transaction is expected to close in the first half of 2026.New Risk • Nov 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-€21k). Revenue is less than US$1m (€15k revenue, or US$18k). Market cap is less than US$10m (€2.00m market cap, or US$2.31m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$289.6k).New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 100% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€67.0k market cap, or US$74.0k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$295.3k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).お知らせ • Jul 12Gour Medical SA announced that it has received €0.135 million in fundingGour Medical SA announced a private placement of 3,375,000 shares at a price of €0.04 per share for gross proceeds of €135,000 on July 10, 2023.New Risk • Jul 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 303% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€536.3k market cap, or US$588.0k).Board Change • Jun 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Oct 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Jul 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • May 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Reboost Blockchain は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測ENXTPA:MLCOT - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202400N/AN/AN/A12/31/202300N/AN/AN/A12/31/202200N/AN/AN/A12/31/202100N/AN/AN/A12/31/202000N/AN/AN/A12/31/201900N/AN/AN/A12/31/2018N/A0N/AN/AN/A12/31/2017N/A0N/AN/AN/A12/31/2016N/A0N/AN/AN/Aアナリストによる今後の成長予測収入対貯蓄率: MLCOTの予測収益成長が 貯蓄率 ( 2.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MLCOTの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MLCOTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MLCOTの収益がFrench市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MLCOTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MLCOTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 01:58終値2026/05/20 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Reboost Blockchain Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • 2hNo independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Jean-Charles Dudek was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 07Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026Reboost Blockchain Corp., Annual General Meeting, Jun 10, 2026. Location: 3 rue d heliopolis, paris France
お知らせ • Feb 17Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction.Pyratzlabs signed a letter of intent to acquire Reboost Blockchain Corp. (ENXTPA:MLCOT) in a reverse merger transaction on February 15, 2026. The transaction is subject to both shareholder approval and regulatory clearance before it can be finalized. The transaction is expected to close in the first half of 2026.
New Risk • Nov 09New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-€21k). Revenue is less than US$1m (€15k revenue, or US$18k). Market cap is less than US$10m (€2.00m market cap, or US$2.31m). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (29% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$289.6k).
New Risk • Dec 31New major risk - Revenue and earnings growthRevenue has declined by 100% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-€82k). Revenue has declined by 100% over the past year. Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€67.0k market cap, or US$74.0k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€268.1k market cap, or US$295.3k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
お知らせ • Jul 12Gour Medical SA announced that it has received €0.135 million in fundingGour Medical SA announced a private placement of 3,375,000 shares at a price of €0.04 per share for gross proceeds of €135,000 on July 10, 2023.
New Risk • Jul 09New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 303% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-€82k). Shareholders have been substantially diluted in the past year (303% increase in shares outstanding). Revenue is less than US$1m (€1.0 revenue, or US$1.0). Market cap is less than US$10m (€536.3k market cap, or US$588.0k).
Board Change • Jun 19No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 25No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Oct 31No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Jul 07No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • May 12No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Gilles Avenard was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.